Your session is about to expire
← Back to Search
Cytokine
GM-CSF for MODS (GRACE Trial)
Phase 4
Waitlist Available
Led By Mark W Hall, MD
Research Sponsored by Nationwide Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up subjects will be screened for immunoparalysis throughout their first three weeks of sepsis-induced mods
Awards & highlights
Summary
This trial will help to establish the dose and route of GM-CSF delivery that is most efficacious in reversing sepsis-induced immunoparalysis in children.
Eligible Conditions
- Sepsis-induced Multiple Organ Dysfunction Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ subjects will be screened for immunoparalysis throughout their first three weeks of sepsis-induced mods
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~subjects will be screened for immunoparalysis throughout their first three weeks of sepsis-induced mods
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
TNF-alpha response
Trial Design
4Treatment groups
Experimental Treatment
Group I: SQ GM-CSF 250 mcg/m2/doseExperimental Treatment1 Intervention
If the SQ 125 mcg/m2/dose arm is not successful in a cohort of subjects (or if the IV dose had to be escalated to 250 mcg/m2/dose), we will transition to 250 mcg/m2/day via the SQ route for 7 consecutive days in a subsequent cohort.
Group II: SQ GM-CSF 125 mcg/m2/doseExperimental Treatment1 Intervention
Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the subcutaneous (SQ) route at a dose of 125 mcg/m2/day for 7 consecutive days.
Group III: IV GM-CSF 250 mcg/m2/doseExperimental Treatment1 Intervention
If the IV 125 mcg/m2/dose arm is not successful in the first cohort of subjects, we will transition to 250 mcg/m2/day via the IV route for 7 consecutive days in a subsequent cohort.
Group IV: IV GM-CSF 125 mcg/m2/doseExperimental Treatment1 Intervention
Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the intravenous (IV) route at a dose of 125 mcg/m2/day for 7 consecutive days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GM-CSF
2014
Completed Phase 4
~1340
Find a Location
Who is running the clinical trial?
Nationwide Children's HospitalLead Sponsor
347 Previous Clinical Trials
5,229,106 Total Patients Enrolled
Mark W Hall, MDPrincipal InvestigatorNationwide Children's Hospital
1 Previous Clinical Trials
108 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a high likelihood of experiencing brain death.You have a confirmed or suspected infection that caused multiple organ dysfunction syndrome (MODS).You have a known condition that weakens your immune system.You are allergic to GM-CSF.You have a medical condition that makes it unsafe for you to receive medications through subcutaneous injection, such as being on extracorporeal membrane oxygenation (ECMO).You have burns that cover more than 5% of your body.
Research Study Groups:
This trial has the following groups:- Group 1: SQ GM-CSF 125 mcg/m2/dose
- Group 2: SQ GM-CSF 250 mcg/m2/dose
- Group 3: IV GM-CSF 125 mcg/m2/dose
- Group 4: IV GM-CSF 250 mcg/m2/dose
Awards:
This trial has 3 awards, including:- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger